Page last updated: 2024-10-25

deferoxamine and Aortic Diseases

deferoxamine has been researched along with Aortic Diseases in 1 studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Aortic Diseases: Pathological processes involving any part of the AORTA.

Research Excerpts

ExcerptRelevanceReference
"We have investigated whether long-term administration of angiotensin (Ang) II causes ferritin induction and iron accumulation in the rat aorta, and their possible relation to regulatory effects on gene expression and vascular function in Ang II-infused animals."1.33Iron chelation suppresses ferritin upregulation and attenuates vascular dysfunction in the aorta of angiotensin II-infused rats. ( Ishizaka, N; Matsuzaki, G; Mori, I; Nagai, R; Ohno, M; Saito, K, 2005)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ishizaka, N1
Saito, K1
Mori, I1
Matsuzaki, G1
Ohno, M1
Nagai, R1

Other Studies

1 other study available for deferoxamine and Aortic Diseases

ArticleYear
Iron chelation suppresses ferritin upregulation and attenuates vascular dysfunction in the aorta of angiotensin II-infused rats.
    Arteriosclerosis, thrombosis, and vascular biology, 2005, Volume: 25, Issue:11

    Topics: Aldehydes; Angiotensin II; Animals; Aorta; Aortic Diseases; Apoferritins; Chemokine CCL2; Deferoxami

2005